Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,458 | -236,928 | -177,478 | -120,723 | -67,992 |
| Depreciation Amortization | 426 | -1,517 | -2,598 | -2,009 | -1,132 |
| Accounts payable and accrued liabilities | 1,678 | 71 | -2,759 | -2,663 | -2,255 |
| Other Working Capital | -765 | -437 | -3,646 | -8,129 | -525 |
| Other Operating Activity | 5,715 | 32,371 | 27,996 | 21,672 | 12,456 |
| Operating Cash Flow | $-46,404 | $-206,440 | $-158,485 | $-111,852 | $-59,448 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 71 | 218 | 155 | 84 | N/A |
| Purchase Of Investment | N/A | -82,868 | -82,868 | -82,868 | -44,385 |
| Sale Of Investment | N/A | 251,170 | 208,587 | 157,341 | 88,545 |
| Investing Cash Flow | $71 | $168,520 | $125,874 | $74,557 | $44,160 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 57,161 | 18,262 | 18,398 | N/A |
| Common Stock Issued | 10,875 | 19,653 | 59 | N/A | N/A |
| Other Financing Activity | 0 | 275 | 0 | 59 | 0 |
| Financing Cash Flow | $10,875 | $77,089 | $18,321 | $18,457 | $N/A |
| Beginning Cash Position | 182,530 | 143,361 | 143,361 | 143,361 | 143,361 |
| End Cash Position | 147,072 | 182,530 | 129,071 | 124,523 | 128,073 |
| Net Cash Flow | $-35,458 | $39,169 | $-14,290 | $-18,838 | $-15,288 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,404 | -206,440 | -158,485 | -111,852 | -59,448 |
| Capital Expenditure | N/A | N/A | -16 | 84 | N/A |
| Free Cash Flow | -46,404 | -206,440 | -158,501 | -111,768 | -59,448 |